Daishi Tian
Clinical trials sponsored by Daishi Tian, explained in plain language.
-
Can a single injection tame stubborn multiple sclerosis?
Disease control Not yet recruitingThis early-stage trial is testing an investigational injection called GT802 in people with relapsing or refractory multiple sclerosis (MS) — meaning their disease is active despite standard treatments. The study aims to check whether GT802 is safe and to get a first look at wheth…
Phase: EARLY_PHASE1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Engineered immune cells take aim at debilitating muscle weakness
Disease control Not yet recruitingThis early-phase trial tests a single infusion of universal STAR-T cells—engineered immune cells—in adults aged 18 to 65 with refractory generalized myasthenia gravis, a condition causing severe muscle weakness. The study aims to assess safety, tolerability, and signs of effectiv…
Phase: PHASE1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Experimental STAR-T cell therapy aims to tame multiple sclerosis
Disease control Not yet recruitingThis early-stage trial will test the safety of a new immune cell therapy called universal STAR-T cells in 24 adults with multiple sclerosis (MS) who have no other treatment options. The therapy involves infusing specially engineered cells that may help control the disease. The st…
Phase: PHASE1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC